Created at 5:53 p.m. Aug, 20, 2024
Author: alitch
Related Note: 1481335817317 1
Rationale for change

Multiple Myeloma is NOT a primary malignacy of the bone. It is called a plasmacytoma when it becomes a lesion that effects the bone, but I would still argue this is not a primary malignancy of bone as it is not primary because it does not originate in the bone. This card either needs to be updated as I have edited it or probably just removed.

Sources via AMBOSS definitions:
Plasma cell dyscrasia: a group of conditions characterized by the abnormal proliferation of the same type (=monoclonal) of a plasma cell that may also secrete a monoclonal immunoglobulin and/or immunoglobulin fragment (e.g., light chain)
Solitary plasmacytoma: an early-stage plasma cell dyscrasia characterized by a single lesion that affects bones (solitary plasmacytoma of bone) or soft tissue (solitary extramedullary plasmacytoma), or in rare cases multiple solitary lesions in soft tissue, bone or both (multiple solitary plasmacytoma)
Multiple myeloma: a malignant plasma cell dyscrasia characterized by uncontrolled proliferation and the diffuse infiltration of monoclonal plasma cells in the bone marrow

Stat pearls: Monoclonal Gammopathy of Undetermined Significance (MGUS)

Serum monoclonal protein less than 3 g/dl
Clonal bone marrow plasma cells less than 10%
No end-organ damage

Smoldering Multiple Myeloma

Monoclonal protein is greater than or equal to 3 g/dl
Clonal bone marrow plasma cells between 10% to 59%
No end-organ damage[22]

Solitary Plasmacytoma

Solitary lesion made up of clonal plasma cells
Normal bone marrow
Negative imaging outside of the single lesion
No end-organ damage

Text Text
Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Empty field
Bootcamp
OME
Additional Resources
One by one
Empty field
#AK_Step2_v12::#UWorld::Step::3943 #AK_Other::Only_Step_1&2_Overlap #AK_Step1_v12::#AMBOSS::yWadLj #AK_Step2_v12::!Shelf::IM::no_dupes #AK_Other::AnKing_Image::AhmedA::Multiple_Myeloma #AK_Step2_v12::#AMBOSS::etaxcm #AK_Step2_v12::#Resources_by_rotation::IM::ome::heme/onc::plasma_cell #AK_Step1_v12::#Low/HighYield::1-HighYield #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::04_Pathology::26_Plasma_cell_dyscrasias::01_Multiple_myeloma #AK_Step1_v12::#Pixorize::01_Biochemistry::19_Plasma_Cell_Dyscrasias::02_Multiple_Myeloma #AK_Step1_v12::#OME::13_Hematology_Oncology::04_Proliferation::05_Plasma_Cell_Dyscrasis #AK_Step1_v12::#NinjaNerd::09_Hematology::02_Pathology::09_Plasma_Cell_Disorders #AK_Step1_v12::#Physeo::11_Pathology::10_HemeOnc_Pathology::18_Plasma_Cell_Dyscrasias #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::10_Plasma_Cell_Dyscrasias_&_Myeloproliferative_Disease::01_Multiple_Myeloma #AK_Other::AnKing_Image::!Subjects::Hematology_&_Oncology::Multiple_Myeloma #AK_Step2_v12::#OME::05_Heme_Onc::07_Plasma_Cell #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::04_Pathology::26_Plasma_cell_dyscrasias #AK_Step1_v12::#Pathoma::06_WBC::08_Plasma_Cell_(Dyscrasias) #AK_Step1_v12::#B&B::15_MSK::03_Pathology::04_Benign_Bone_Tumors #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::04_Oncology::05_Plasma_Cell_Dyscrasias_SOAP #AK_Step2_v12::#AMBOSS::SF0yh3 #AK_Step1_v12::^Systems::HemeOnc::WBC #AK_Step2_v12::Original_decks::Dorian::im::ome::heme/onc::plasma_cell #AK_Step1_v12::#AMBOSS::x4aElk #AK_Other::AnKing_Image::AhmedK::Multiple_Myeloma #AK_Step1_v12::#OME::PreClinical::13_Hematology_Oncology::04_Proliferation::05_Plasma_Cell_Dyscrasis #AK_Step1_v12::#SketchyPath::10_Myeloid_&_Lymphoid::02_Lymphoid_&_Plasma_Cell_Disorders::04_Plasma_Cell_Neoplasms #AK_Other::#AK_Original_Decks::Step_1::Zanki_Step_Decks::Zanki_Hematology_&_Oncology::Pathoma_WBC #AK_Other::AnKing_Image::!Subjects::Hematology_and_Oncology::Multiple_Myeloma #PANCE::HEME::neoplasms_premalignancies_malignancies